Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis
Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer
Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer
View: Text | PDF
Research Article Microbiology Pulmonology

Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis

  • Text
  • PDF
Abstract

Pulmonary fibrosis is a chronic and often fatal disease. The pathogenesis is characterized by aberrant repair of lung parenchyma, resulting in loss of physiological homeostasis, respiratory failure, and death. The immune response in pulmonary fibrosis is dysregulated. The gut microbiome is a key regulator of immunity. The role of the gut microbiome in regulating the pulmonary immunity in lung fibrosis is poorly understood. Here, we determine the impact of gut microbiota on pulmonary fibrosis in substrains of C57BL/6 mice derived from different vendors (C57BL/6J and C57BL/6NCrl). We used germ-free models, fecal microbiota transplantation, and cohousing to transmit gut microbiota. Metagenomic studies of feces established keystone species between substrains. Pulmonary fibrosis was microbiota dependent in C57BL/6 mice. Gut microbiota were distinct by β diversity and α diversity. Mortality and lung fibrosis were attenuated in C57BL/6NCrl mice. Elevated CD4+IL-10+ T cells and lower IL-6 occurred in C57BL/6NCrl mice. Horizontal transmission of microbiota by cohousing attenuated mortality in C57BL/6J mice and promoted a transcriptionally altered pulmonary immunity. Temporal changes in lung and gut microbiota demonstrated that gut microbiota contributed largely to immunological phenotype. Key regulatory gut microbiota contributed to lung fibrosis, generating rationale for human studies.

Authors

Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer

×

Figure 5

Horizontal transmission of gut microbiota can modify experimental outcomes in lung fibrosis models.

Options: View larger image (or click on image) Download as PowerPoint
Horizontal transmission of gut microbiota can modify experimental outcom...
16S rRNA amplicon sequencing of feces and lung fibrosis outcomes after bleomycin treatment. (A) C57BL/6J and C57BL/6Cr mice were randomly assigned 1:1 to shared cages for mixing, while the remaining original cohort of C57BL/6J and C57BL/6Cr mice were left in the same cages for 3 weeks. (B) Gut microbiota demonstrates distinct community composition by PCA and ordination at baseline. (C) Shannon diversity is significantly greater in CR mice at baseline. (D) PCA and ordination demonstrate a coalescence of gut microbial communities in shared mixed cages, with C57BL/J original cages remaining significantly altered. (E) Cohousing increases diversity in BL/6J mice housed. (F) Increased operational taxonomic units (OTUs) identified in mixed C57BL/6J mice. (G) Survival after bleomycin, mixed BL/6J mice have improved survival. (H) Whole-lung IL-6 is reduced in mixed BL/6J mice. (I) PCA of GSEA enriched immunological signatures in original BL/6J and BL/6Cr mice compared with all mixed mice (permutational multivariate analysis of variance [PERMANOVA] P = 0.02 for BL/6J compared with BL/6Cr). (J) Study schematic. (K) PCA and ordination of BL/6J mice from day 0 of cohousing with BL/6Cr mice to day 21. (L and M) Changes in taxa over time in BL/6J mice mixed with BL/6Cr mice. (N) Reduced mortality in BL/6J FMT recipients from BL/6NCrl donors compared with BL/6J non-FMT controls, log rank P = 0.04 BL/6J recipients (30% mortality) versus BL/6J control (70% mortality). (O) Reduced lung collagen content in BL/6J recipients. (P) Significant horizontal transfer of OTUs by FMT. (Q) Increased similarity in BL/6J FMT recipients compared with BL/6NCrl donors on FMT to BL/6J from NCrl donors measured by Bray-Curtis dissimilarity. (A–Q n = 10 per group.) Box plots show the interquartile range (box), median (line), and minimum and maximum (whiskers). PERMANOVA (B, D, and I), unpaired t test or Mann-Whitney test (C, H, L, and M), ANOVA (E, F, and O–Q), log rank t test (G and K). *P < 0.05, **P < 0.01, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts